Literature DB >> 11053098

Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.

K W Selmaj1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11053098      PMCID： PMC1766612          DOI： 10.1136/ard.59.suppl_1.i94

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  39 in total

1.  Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

Authors:  K Selmaj; C S Raine; B Cannella; C F Brosnan
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

2.  Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.

Authors:  K Selmaj; C S Raine; A H Cross
Journal:  Ann Neurol       Date:  1991-11       Impact factor: 10.422

3.  Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy.

Authors:  M Matsuda; N Tsukada; K Miyagi; N Yanagisawa
Journal:  J Neuroimmunol       Date:  1994-06       Impact factor: 3.478

4.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

Authors:  K M Mohler; D S Torrance; C A Smith; R G Goodwin; K E Stremler; V P Fung; H Madani; M B Widmer
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

Review 5.  Tumor necrosis factor: receptors and inhibitors.

Authors:  H Loetscher; M Steinmetz; W Lesslauer
Journal:  Cancer Cells       Date:  1991-06

6.  Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  N Tsukada; M Matsuda; K Miyagi; N Yanagisawa
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

7.  Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility.

Authors:  J B Peter; F N Boctor; W W Tourtellotte
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

8.  Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin.

Authors:  K Selmaj; C S Raine; M Farooq; W T Norton; C F Brosnan
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

9.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.

Authors:  D Aderka; H Engelmann; Y Maor; C Brakebusch; D Wallach
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

10.  Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.

Authors:  T J Evans; D Moyes; A Carpenter; R Martin; H Loetscher; W Lesslauer; J Cohen
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307
View more
  7 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

Review 2.  Anti-tumor necrosis factor alpha-associated multiple sclerosis.

Authors:  David S Titelbaum; Alexandra Degenhardt; R Philip Kinkel
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

3.  Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis.

Authors:  Katerina Akassoglou; Ryan A Adams; Jan Bauer; Peter Mercado; Vivian Tseveleki; Hans Lassmann; Lesley Probert; Sidney Strickland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

4.  Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy.

Authors:  Alexander Winkelmann; Robert Patejdl; Sabine Wagner; Reiner Benecke; Uwe Klaus Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

5.  Go-sha-jinki-Gan Alleviates Inflammation in Neurological Disorders via p38-TNF Signaling in the Central Nervous System.

Authors:  Shiying Jiang; Kousuke Baba; Keisuke Hagihara; Hideki Mochizuki; Tatsusada Okuno; Makoto Kinoshita; Chi-Jing Choong; Hideki Hayakawa; Hiroshi Sakiyama; Kensuke Ikenaka; Seiichi Nagano; Tsutomu Sasaki; Munehisa Shimamura; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2020-10-20       Impact factor: 7.620

Review 6.  Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.

Authors:  Justin R Siebert; Amanda Conta Steencken; Donna J Osterhout
Journal:  Biomed Res Int       Date:  2014-09-18       Impact factor: 3.411

7.  Arctigenin Exerts Neuroprotective Effect by Ameliorating Cortical Activities in Experimental Autoimmune Encephalomyelitis In Vivo.

Authors:  Liangpeng Wei; Zhenyi Xue; Baihui Lan; Shiyang Yuan; Yuanyuan Li; Cunle Guo; Rongxin Zhang; Ran Ding; Hui Shen
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.